NCT01438554已完成1 期
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 个研究点 分布在 1 个国家目标入组 89 人开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 89
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose (MTD) of pazopanib and GSK1120212 when combined in patients with solid tumors
研究概览
简要总结
The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dose escalation cohort for all solid tumors is closed to enrollment.
- •Expansion cohorts: Soft-tissue sarcoma, cholangiocarcinoma, and differentiated thyroid cancer (DTC) cohorts are closed to enrollment. Patients in the DTC cohort must have disease that is able to be biopsied.
- •Must have measurable disease.
- •Tumor progression in the 6-month period prior to study drug initiation.
- •DTC patients: must have radioiodine non-avid lesions, OR radioiodine avid lesions that have not responded to treatment with radioactive iodine.
- •ECOG performance status less than or equal to
- •Life expectancy >3 months.
- •Blood pressure <140 mmHg and <90 mmHg.
- •LVEF is >= 50%
- •Must be able to swallow pills.
排除标准
- •Chemotherapy, radiotherapy, other investigational therapy, or major surgery within 4 weeks.
- •Sarcoma and cholangiocarcinoma ONLY: Prior VEGF-targeted TKI therapy.
- •Pregnant or currently breastfeeding.
- •Unresolved toxicity greater than grade
- •Evidence of active hepatitis or HIV.
- •Significant cardiovascular disease.
- •Taking medications known to be strong inducers or inhibitors of CYP3A enzymes.
- •Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding.
- •History of gastrointestinal condition causing malabsorption or obstruction.
- •Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep vein thrombosis (DVT) within past 6 months.
- •Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase risk of pulmonary hemorrhage.
- •Hemoptysis within 6 months of starting treatment.
- •History of retinal vein occlusion (RVO) or central serous retinopathy (CSR), or predisposing factors to RVO or CSR as assessed by ophthalmic exam.
- •Known brain mets that are not stable for at least 8 weeks prior to treatment, or patient is on glucocorticoids for brain mets.
研究组 & 干预措施
Pazopanib and GSK1120212
Experimental
Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
干预措施: Pazopanib (Drug)
Pazopanib and GSK1120212
Experimental
Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
干预措施: GSK1120212 (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD) of pazopanib and GSK1120212 when combined in patients with solid tumors
时间窗: Approximately one year
Adverse events as a measure of the safety and tolerability profile of pazopanib in combination with GSK1120212 in patients with solid tumors
时间窗: Approximately two years
次要结局
- Objective response rate at six months in patients with advanced thyroid cancer, soft tissue sarcoma and cholangiocarcinoma being treated at the MTD(Approximately one year)
- Progression-free survival (PFS) in patients with advanced thyroid cancer, soft tissue sarcoma and cholangiocarcinoma being treated at MTD.(Approximately one year)
- PD marker analysis on peripheral blood mononuclear cells for patients with soft tissue sarcoma and cholangiocarcinoma(Approximately one year)
- Correlation of PK data with radiographic response, PD markers, and the impact of tumor histologic subtype and tumor genotype on radiographic response for patients with advanced thyroid cancer(Approximately one year)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor - Protocol SpecificBreast Cancer - FemaleNCT01407562Rutgers, The State University of New Jersey34
已完成
1 期
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsAdvanced CancersNCT01454804M.D. Anderson Cancer Center43
已完成
1 期
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid TumorsLung Cancer, Non-Small CellNCT00619424GlaxoSmithKline58
已完成
1 期
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to TreatmentChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorMetastatic Childhood Soft Tissue SarcomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Visual Pathway GliomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00929903National Cancer Institute (NCI)55
已完成
2 期
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic ChondrosarcomaChondrosarcomaMetastatic ChondrosarcomaNCT01330966George Clinical Pty Ltd47